# US 2012/0230917 A1 · Compositions that include a hydrophobic compound and a polyamino acid conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0230917 A1
- Document ID: US20120230917A1
- Status: Published application
- Kind: A1
- Application number: 13/475,672
- Filed: 2012-05-18
- Published: 2012-09-13
- Earliest claimed: 2007-05-09
- Assignees: Nitto Denko Corporation
- Inventors: Sang Van; Yucheng Song; Xinghe Wang; Zheng Hou; Zhongling Feng; Gang Zhao; Lei Yu
- Web page: https://patentgrep.com/patent/US20120230917A1

## CPC

- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/085: {conjugated systems}
- A61K 49/146: {the peptide being a polyamino acid, e.g. poly-lysine}
- A61K 49/1824: {coated or functionalised nanoparticles (liposomes A61K49/1812; nanoemulsions A61K49/1806; micelles A61K49/1809)}
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Various compositions that include a hydrophobic compound and a polyamino acid conjugate are prepared. The compositions described herein are useful for a variety of drug, biomolecule, and imaging agent delivery applications.

## Claims

### Claim 1

A composition comprising a first anticancer drug, a second anticancer drug and a polymer conjugate, wherein:
the polymer conjugate comprises a polymeric matrix that non-covalently entraps at least a portion of the first anticancer drug therein;
the polymer conjugate comprises a recurring unit of the formula (I):
wherein:
one of R1 and R2 is the second anticancer drug; and
the other one of R1 and R2 is hydrogen or an alkali metal.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the polymer conjugate further comprises a recurring unit of the formula (II):
wherein each R3 and each R4 are each independently hydrogen or an alkali metal.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the polymer conjugate further comprises a recurring unit of the formula (III):
wherein each R7 is hydrogen or an alkali metal.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the polymer conjugate includes include about 1 mole % to about 50 mole % of the recurring unit of formula (III) based on the total moles of recurring units of formulae (I), (II), and (III).

### Claim 5 (depends on 1)

The composition of claim 1, wherein the first anticancer drug has a chemical structure that is the same as that of the second anticancer drug.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the first anticancer drug and the second anticancer drug are independently selected from the group consisting of a taxane, a camptotheca, and an anthracycline.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the first anticancer drug and the second anticancer drug is a taxane.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the first anticancer drug and the second anticancer drug is a paclitaxel.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the number of recurring units of the formula (I) and the number of recurring units of formula (II) in the polymer conjugate are each independently in the range of from about 50 to about 5,000.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the number of recurring units of the formula (I) and the number of recurring units of formula (II) in the polymer conjugate are each independently in the range of from about 100 to about 2,000.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the polymer conjugate consists of a recurring unit of formula (I) and a recurring unit of formula (II).

### Claim 12 (depends on 1)

The composition of claim 1, wherein the first anticancer drug is present in an amount in the range of about 5% to about 40% (weight/weight) based on the mass ratio of the first anticancer drug to the combined weight of the first anticancer drug and the polymer conjugate.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the first anticancer drug is present in an amount in the range of about 10% to about 30% (weight/weight) based on the mass ratio of the first anticancer drug to the combined weight of the first anticancer drug and the polymer conjugate.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the polymer conjugate comprises an amount of the second anticancer drug in the range of about 5% to about 40% (weight/weight) based on the mass ratio of the second anticancer drug to the combined weight of the first anticancer drug and the polymer conjugate.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the polymer conjugate comprises an amount of the second anticancer drug in the range of about 10% to about 30% (weight/weight) based on the mass ratio of the second anticancer drug to the combined weight of the first anticancer drug and the polymer conjugate.

### Claim 16 (depends on 1)

A method of making the composition of claim 1, comprising the steps of:
at least partially dissolving the polymer conjugate in a solvent; and
intermixing the first anticancer drug with the at least partially dissolved polymer conjugate to form a mixture.

### Claim 17 (depends on 1)

A method of treating, ameliorating or diagnosing a disease or condition, comprising administering an effective amount of the composition of claim 1 to a mammal in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or condition is selected from the group consisting of lung cancer, breast cancer, colon cancer, ovarian cancer, prostate cancer, and melanoma.

### Claim 19 (depends on 17)

The method of claim 17, wherein the disease or condition is melanoma.

### Claim 20 (depends on 17)

The method of claim 17, wherein the composition is administered intravenously.
